Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06643884 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Suprachoroidal Administration in Subjects With Metastases to the Choroid

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 10 → 13 locations
    • Eligibility criteria expanded, about 11 words
  2. Site details revised at 1 of 10 sites
    • Study description expanded, about 1 word
    v5
  3. Primary completion date: Mar 31, 2026 to Nov 30, 2026
    • Study sites: 9 to 10
    • Study completion date: Feb 28, 2027 to Oct 31, 2027
    • Study arms: 5 to 7
    v4
  4. Trial status: Not Yet Recruiting to Recruitingv3 Show 7 more changesShow less
    • Primary completion date: Jan 31, 2026 to Mar 31, 2026
    • Study completion date: Dec 30, 2026 to Feb 28, 2027
    • Start date changed from estimate of Oct 25, 2024 to Dec 16, 2024
    • Study description revised
    • Study sites revised (9)
    • Eligibility criteria expanded, about 1 word
    • Study title shortened, about 4 words
  5. Study title shortened, about 6 wordsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Trial Details
NCT Number NCT06643884
Lead Sponsor Aura Biosciences
Conditions
(from sponsor)		 Eye Cancer, Primary Cancer
Related terms Eye Neoplasms, Neoplasms
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov